Safety and tolerability of Miltuximab® - a first in human study in patients with advanced solid cancers | ||
| Asia Oceania Journal of Nuclear Medicine and Biology | ||
| مقاله 1، دوره 9، شماره 2، مهر 2021، صفحه 86-100 اصل مقاله (1.23 M) | ||
| نوع مقاله: Original Article | ||
| شناسه دیجیتال (DOI): 10.22038/aojnmb.2021.55600.1386 | ||
| نویسندگان | ||
| Dhanusha Sabanathan1؛ Douglas H Campbell2؛ Vicki M Velonas2؛ Sandra Wissmueller2؛ Hubert Mazure2؛ Marko Trifunovic3؛ Pirooz Poursoltan1؛ Kevin Ho-Shon1؛ Tiffany R Mackay2؛ Maria E Lund2؛ Yanling Lu2؛ Paul J Roach4؛ Dale L Bailey4؛ Bradley J Walsh2؛ David Gillatt1؛ Howard Gurney* 1 | ||
| 1Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia | ||
| 2GlyTherix Ltd, 75 Talavera Road, Macquarie Park, Sydney, Australia | ||
| 3Macquarie Medical Imaging, Macquarie, Sydney, Australia | ||
| 4PharmaScint, Sydney, Australia | ||
| چکیده | ||
| Objective(s): Miltuximab® is a chimeric antibody targeting Glypican-1 (GPC-1), a cell surface antigen which is overexpressed in solid cancers. Miltuximab® has shown promising safety and efficacy in radioimmunotherapy models of prostate cancer. This first in human study used Miltuximab® radiolabelled with Gallium-67 ([67Ga]Ga-DOTA-Miltuximab®). The primary study endpoint was to establish safety and tolerability of Miltuximab®. Secondary endpoints were biodistribution, tumour targeting and pharmacokinetic analysis. Methods: Four cohorts of three patients (9 with advanced prostate cancer, 2 with pancreatic and 1 with bladder cancer) were dosed with 1 mg, ~250 MBq of [67Ga]Ga-DOTA-Miltuximab®. Cohort 1 received [67Ga]Ga-DOTA-Miltuximab® alone, while cohorts 2-4 were pre-infused with increasing doses (3.5, 11.5 and 24 mg, respectively) of unlabelled Miltuximab®-DOTA 1 hour prior to [67Ga]Ga-DOTA-Miltuximab®. Safety and tolerability were assessed by clinical and standard laboratory assessments. Patients underwent whole body gamma-camera scans and SPECT/CT scans up to 144 h post-infusion. Total organ radiation exposure was determined by dosimetry of whole-body gamma scans. Results: The dosing regimen was well tolerated, with no drug-related adverse events observed. Liver and spleen uptake of [67Ga]Ga-DOTA-Miltuximab® was observed. Liver uptake was reduced by pre-infusion of unlabelled Miltuximab®-DOTA. Dosimetry analysis showed a favorable exposure profile. [67Ga]Ga-DOTA-Miltuximab® targeting to tumour sites was observed in two prostate cancer patients who had failed enzalutamide treatment. Higher doses of unlabelled antibody achieved lower liver uptake and increased antibody serum half life. Conclusions: This study is the first in human for Miltuximab® a first in class antibody targeting GPC-1. The trial met its primary endpoint of safety, demonstrating its potential as a safe and tolerable monoclonal antibody. This safety data, together with targeting to tumour lesions and biodistribution information supports the further clinical development of Miltuximab® as a theranostic agent in a planned Phase I human trial. Trial registration: ANZCTR, ACTRN12616000787482, https://www.anzctr.org. | ||
| کلیدواژهها | ||
| Miltuximab®؛ Monoclonal antibody؛ Theranostic؛ Solid tumours؛ Glypican-1 | ||
|
سایر فایل های مرتبط با مقاله
|
||
| مراجع | ||
|
1. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol. 1992; 10(7):1066–73.
2. Bellmunt J, De Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017; 376(11): 1015–26.
3. Sabanathan D, Nagrial AM, Chin VT. The changing landscape of systemic therapy in advanced pancreatic cancer. Cancer Forum. 2016; 40:53–8.
4. Nixon NA, Blais N, Ernst S, Kollmannsberger C, Bebb G, Butler M, et al. Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr Oncol. 2018; 25(5):e373–84 .
5. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood. 2003; 101(2): 391–8.
6. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support. N Engl J Med. 1993; 329(17):1219–24.
7. Massicano A, Pujatti P, Alcarde L, Suzuki M, Spencer P, Araújo E. Development and biological studies of 177Lu-DOTA-rituximab for the treatment of Non-Hodgkin’s lymphoma. Curr Radiopharm. 2015; 9(1): 54–63.
8. Forrer F, Oechslin-Oberholzer C, Campana B, Maecke HR, Mueller-Brand J, Lohri A. Is there need for radioimmunotherapy? Results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab. Q J Nucl Med Mol Imaging. 2012; 56(6):544–50.
9. Forrer F, Chen J, Fani M, Powell P, Lohri A, Müller-Brand J, et al. In vitro charac-terization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. Eur J Nucl Med Mol Imaging. 2009; 36(9):1443–52.
10. Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005; 46(5):850–8.
11. A.P. Breeman W, Sze Chan H, M.S. de Zanger R, K. Konijnenberg M, de Blois E. Overview of Development and Formulation of 177Lu-DOTA-TATE for PRRT. Curr Radiopharm. 2015; 9(1):8–18.
12. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2):125–35.
Miltuximab® First in Human Trial Sabanathan D et al
Asia Ocean J Nucl Med Biol. 2021; 9(2):86-100 99
13. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Büchler MW, Lander AD, et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest. 1998 1; 102(9):1662-73.
14. Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001; 61(14): 5562–9.
15. Lund ME, Campbell DH, Walsh BJ. The role of glypican-1 in the tumour micro-environment. In: Advances in Experimental Medicine and Biology. 2020. p. 163–76.
16. Lu H, Niu F, Liu F, Gao J, Sun Y, Zhao X. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma. Cancer Med. 2017; 6(6):1181–91.
17. Hara H, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Nakatsuka R, et al. Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma. Br J Cancer. 2016; 115(1):66–75.
18. Saito T, Sugiyama K, Hama S, Yamasaki F, Takayasu T, Nosaka R, et al. High Expression of Glypican-1 Predicts Dis-semination and Poor Prognosis in Glioblastomas. World Neurosurg.2017; 105: 282–8.
19. Russell PJ, Ow KT, Tam PN, Juarez J, Kingsley EA, Qu CF, et al. Immuno-histochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer. Cancer Immunol Immunother. 2004; 53(11):995–1004.
20. Kato D, Yaguchi T, Iwata T, Katoh Y, Morii K. GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. Elife. 2020; 9: e49392.
21. Harada E, Serada S, Fujimoto M, Takahashi Y, Takahashi T, Hara H, et al. Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma. Oncotarget. 2017; 8(15):24741–52.
22. Yeh MC, Tse BWC, Fletcher NL, Houston ZH, Lund M, Volpert M, et al. Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1). EJNMMI Res. 2020; 10(1):46.
23. Russell PJ, Davis K, Kingsley E, Humphreys J, Hanley J, O’Grady H, et al. Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer. Cell Biophys. 1994; 24–25(1–3):155–61.
24. Li Y, Song E, Rizvi SMA, Power CA, Beretov J, Raja C, et al. Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bi-labeled multiple targeted α radioimmunoconjugates. Clin Cancer Res. 2009; 15(3):865–75.
25. Lightfoot D V., Walker KK, Boniface GR, Hetherington EL, Izard ME, Russell PJ. Dosimetric and therapeutic studies in nude mice xenograft models with 153Samarium-labelled monoclonal antibody, BLCA-38. Antib Immunoconjugates Radio-pharm. 1991; 4:319–30.
26. Walker KZ, Russell PJ. WO 90/14433 Monoclonal Antibodies Which Recognise Malignant Cells from Bladder Carcinomas. European Patent; WO 90/14433, 1990. p. 1–76.
27. Carter T, Sterling-Levis K, Ow K, Doughty L, Hattarki M, Shapira D, et al. Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody. Cancer Immunol Immunother. 2004; 53(6):533–42.
28. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. PhaseI Trial of 177 Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients with Androgen-Independent Prostate Cancer. J Clin Oncol. 2005; 23(21):4591–601.
29. Tagawa ST, Milowsky MI, Morris M, Vallab-
hajosula S, Christos P, Akhtar NH, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013; 19(18):5182–91.
30. Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM, et al. Radioimmunotherapy of Metastatic Prostate Cancer with 177 Lu-DOTA- huJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Curr Radio-pharm. 2016; 9(1):44–53.
31. Bailey DL, Sabanathan D, Aslani A, Campbell
DH, Walsh BJ, Lengkeek NiA. RetroSPECT: Gallium-67 as a Long-Lived Imaging Agent for Theranostics. Asia Ocean J Nuc Med Biol. 2021; 9(1): 1-8.
32. Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen
Sabanathan D et al Miltuximab® First in Human Trial
100 Asia Ocean J Nucl Med Biol. 2021; 9(2):86-100
antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005; 11(20):7454–61.
33. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46(6):1023–7.
34. ARSAC. Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources. Public Heal Engl. 2018.
35. Matsuzaki S, Serada S, Hiramatsu K, Nojima S, Matsuzaki S, Ueda Y, et al. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer. Int J Cancer. 2018; 142(5):1056–66.
36. O’Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schöder H, Larson SM, et al. Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer. J Nucl Med. 2018; 59(1):161–6.
37. Pandit-taskar N, O’Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, et al. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 41(11):2093–105.
38. Information for workers .https://www. arpansa.gov.au/our-services/monitoring/ australian-national-radiation-dose-register /information-for-workers
39. Baum RP, Hertel A, Lorenz M, Schwarz A, Encke A, Hör G. 99Tcm-labelled anti-CEA monoclonal antibody for tumour immune-scintigraphy: First clinical results. Nucl Med Commun. 1989; 10(5):345–52.
40. Wong JYC, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, et al. A phase I trial of 90Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with
metastatic CEA-producing malignancies. Cancer Biother Radiopharm. 2006; 21(2): 88–100.
41. Makris NE, Boellaard R, Van Lingen A, Lammertsma AA, Van Dongen GAMS, Verheul HM, et al. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-Cetuximab. J Nucl Med. 2015; 56(2):249–54 .
42. Pandit-Taskar N, O’Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, et al. Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy. J Nucl Med. 2008; 49(7):1066–74.
43. Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, et al. Phase 1/2 study of fractionated dose lutetium-177–labeled anti–prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019; 125(15): 2561–2569.
44. Pandit-Taskar N, O’Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, et al. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clin Cancer Res. 2015; 21(23): 5277–85.
45. Campbell D, Sabanathan D, Gurney H, Gillatt D, Trifunovic M, Poursoultan P, et al. Outcomes of the Miltuximab first in human trial and proposed study design for a Phase I trial 89Zr/ 177Lu theranostic trial. J Clin Oncol. 2019; 37: 261–261.
46. Saito T, Sugiyama K, Hama S, Yamasaki F, Takayasu T, Nosaka R, et al. High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas. World Neurosurg. 2017; 105: 282–8. | ||
|
آمار تعداد مشاهده مقاله: 1,401 تعداد دریافت فایل اصل مقاله: 698 |
||
